Tylvalosin Tartrate Improves the Health Status of Swine Herds during Immunization with Porcine Reproductive and Respiratory Syndrome Virus-Inactivated Vaccine

Simple Summary Variants of porcine reproductive and respiratory syndrome virus (PRRSV) strains complicate measures taken to control PRRS. In recent years, tylvalosin tartrate has been used to control PRRSV infection in swine farms as well as to improve the swine herd's status during PRRSV vaccination. To investigate the effect of tylvalosin tartrate during PRRSV-inactivated vaccine immunization, we fed piglets a diet medicated with tylvalosin tartrate during PRRSV-inactivated vaccine immunization. The cumulative data showed that tylvalosin tartrate attenuated the increase in total white blood cells induced by immunization at day one post-immunization (DPI), induced an increase in monocyte counts after seven DPI, and attenuated the intensity of the inflammatory response induced by vaccination and increased IFN-gamma expression at three and seven DPI. In addition, the administration of tylvalosin tartrate could also attenuate the reduction in the percentage of CD8(+) T cells induced by PRRSV-inactivated vaccine immunization at seven DPI. These results demonstrated that the combination of inactivated PRRSV vaccines with tylvalosin tartrate could improve the function of the immune system in piglets and improve the health status of swine herds during PRRSV-inactivated vaccine immunization. Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease that affects pigs and is responsible for severe economic losses. The commercial PRRSV-inactivated vaccine (CH-1a strain) in China was recently selected to control PRRS in large populations of PRRS-positive sows and was found to effectively reduce the rate of stillbirth abortion based on clinical observations. However, stress from vaccine inoculation (e.g., fever, anorexia, abortions, and slow body weight gain) usually appears after immunization on many swine farms. In this study, we fed piglets a diet medicated with tylvalosin tartrate during PRRSV-inactivated vaccine immunization. We found that tylvalosin tartrate attenuated the increase in total white blood cells induced by immunization at day one post-immunization (DPI) and induced an increase in monocyte counts after seven DPI. There was also attenuation in the intensity of the inflammatory response induced by vaccination and elevation of serum IFN-gamma concentrations at three and seven DPI after immunization. The administration of tylvalosin tartrate could also attenuate the reduction in the percentage of CD8(+) T cells induced by PRRSV-inactivated vaccine immunization at seven DPI. These results demonstrated that in addition to tylvalosin tartrate being able to control respiratory and enteric bacterial infections in swine farms, it can also improve the stress status of swine herds during PRRSV-inactivated vaccine immunization.

Automated summary

The variants of PRRSV strains make it difficult to control PRRS. Tylvalosin tartrate has been used to control PRRSV infection and improve the swine herd's status during PRRSV vaccination.